J. Martin-Babau
YOU?
Author Swipe
View article: Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI) Open
PRODIGE 62-OESIRI trial showed low efficacy of paclitaxel and 5FU Nal-IRI in the 2nd line treatment of mESCC, though paclitaxel provided a better safety profile. Trial registration NCT03719924.
View article: 7MO Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): Final results of the randomised phase II PANIRINOX-UCGI28 study
7MO Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): Final results of the randomised phase II PANIRINOX-UCGI28 study Open
View article: Sizing and concentration analysis of <scp>cfDNA</scp> using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer
Sizing and concentration analysis of <span>cfDNA</span> using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer Open
Locally advanced esophageal carcinoma remains of poor prognosis correlated with tumor stage. Albeit liquid biopsy approach offers promising results to monitor high‐risk patients in various solid tumors, the lack of specific mutation in eso…
View article: Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer Open
Aim: Trifluridine/tipiracil-bevacizumab is a standard of care in metastatic colorectal cancer (mCRC) after chemotherapy failure. We aim to assess the addition of XB2001 (anti-IL-1 alpha monoclonal antibody) plus trifluridine/tipirac…
View article: Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol
Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol Open
View article: CN15 Real-life clinical and organizational evaluation of telemonitoring and assisted telemonitoring in more than 1500 cancer patients
CN15 Real-life clinical and organizational evaluation of telemonitoring and assisted telemonitoring in more than 1500 cancer patients Open
View article: First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial Open
Although patients with microsatellite instable metastatic colorectal cancer (CRC) benefit from immune checkpoint blockade, chemotherapy with targeted therapies remains the only therapeutic option for microsatellite stable (MSS) tumors. The…
View article: Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study Open
Abemaciclib + ET significantly improved IDFS in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer, with an acceptable safety profile. Ki-67 index was pr…
View article: Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer
Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer Open
This cohort study found that tumor burden differed between patients who received an mCRC diagnosis before vs after the first COVID-19 lockdown in France. The findings of this study suggest that CRC is a major area for intervention to minim…
View article: 508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)
508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC) Open
View article: The tumor burden of metastatic colorectal cancer patients at initial diagnosis, pre- versus post-Covid-19 lockdown
The tumor burden of metastatic colorectal cancer patients at initial diagnosis, pre- versus post-Covid-19 lockdown Open
Background The COVID-19 pandemic led to a significant reduction in the provision of screening, case identification and hospital referrals to cancer patients. To our knowledge, no study has yet correlated quantitatively the consequences of …
View article: First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study Open
View article: Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study Open
// Juliette Palle 1 , David Tougeron 2 , Astrid Pozet 3 , Emilie Soularue 4 , Pascal Artru 5 , Florence Leroy 6 , Olivier Dubreuil 7 , Matthieu Sarabi 8 , Nicolas Williet 9 , Sylvain Manfredi 10 , Jerome Martin-Babau 11 , Christine Rebisch…
View article: Eribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort
Eribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort Open
View article: Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study
Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study Open
View article: Accuracy of height estimation and tidal volume setting using anthropometric formulas in an ICU Caucasian population
Accuracy of height estimation and tidal volume setting using anthropometric formulas in an ICU Caucasian population Open